Neurocrine Biosciences, Inc. NBIX
167.40 USD -2.00 (-1.18%)
At closeNov 13, 2026, 5:23 PM EST
167.40 0.00 0.00%
After hours · Nov 13, 5:23 PM ET
164.65 Day range 171.16
123.10 52-week range 185.50
- YTD
- +18.03%
- 1 year
- +16.11%
News
benzinga.com Morgan Stanley Maintains Equal-Weight on Neurocrine Biosciences, Raises Price Target to $191 Morgan Stanley analyst Jeffrey Hung maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Equal-Weight and raises the price target from $185 to $191.
zacks.com NBIX or GRDN: Which Is the Better Value Stock Right Now? Investors interested in stocks from the Medical - Drugs sector have probably already heard of Neurocrine Biosciences (NBIX) and Guardian Pharmacy Services (GRDN). But which of these two stocks…
prnewswire.com Neurocrine Biosciences to Present at the 2026 Jefferies Global Healthcare Conference SAN DIEGO, Nov. 10, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that its executives will participate at the 2026 Jefferies Global Healthcare Conference in London…
zacks.com Looking for a Growth Stock? 3 Reasons Why Neurocrine (NBIX) is a Solid Choice Neurocrine (NBIX) could produce exceptional returns because of its solid growth attributes.
zacks.com All You Need to Know About Neurocrine (NBIX) Rating Upgrade to Buy Neurocrine (NBIX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
zacks.com NBIX vs. GRDN: Which Stock Is the Better Value Option? Investors looking for stocks in the Medical - Drugs sector might want to consider either Neurocrine Biosciences (NBIX) or Guardian Pharmacy Services (GRDN). But which of these two companies is the…
zacks.com Wall Street Analysts See a 25.53% Upside in Neurocrine (NBIX): Can the Stock Really Move This High? The average of price targets set by Wall Street analysts indicates a potential upside of 25.5% in Neurocrine (NBIX). While the effectiveness of this highly sought-after metric is questionable, the…
benzinga.com Neurocrine Biosciences Releases Findings From New Survey Showing Adults With Tardive Dyskinesia Reported Fewer Disruptions To Work, School After Starting Treatment With INGREZZA Capsules Survey reveals work or school disruptions among adults with tardive dyskinesia declined from 57% before treatment to 21% after starting INGREZZA, with average missed days per month decreasing from…- benzinga.com Guggenheim Maintains Buy on Neurocrine Biosciences, Raises Price Target to $224 Guggenheim analyst Delma Caiati maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and raises the price target from $207 to $224.
benzinga.com Morgan Stanley Maintains Equal-Weight on Neurocrine Biosciences, Raises Price Target to $185 Morgan Stanley analyst Jeffrey Hung maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Equal-Weight and raises the price target from $183 to $185.
benzinga.com Nasdaq 100 Gets a Lift As Nvidia Overtakes Apple: Stock Market Today Apple's memory-cost margin warning hands Nvidia the top market value as chipmakers rebound. Here's what's happening in the stock market today.
benzinga.com Fabrinet, EverQuote, Lattice Semiconductor, Fiserv And Other Big Stocks Moving Higher On Tuesday U.S. stocks mixed as Dow fell 200 points; Fabrinet surged 13.7% on strong results, guidance and buyback, while several small caps rallied.- benzinga.com RBC Capital Maintains Outperform on Neurocrine Biosciences, Raises Price Target to $190 RBC Capital analyst Brian Abrahams maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Outperform and raises the price target from $187 to $190.
- benzinga.com Canaccord Genuity Maintains Buy on Neurocrine Biosciences, Raises Price Target to $220 Canaccord Genuity analyst Sumant Kulkarni maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and raises the price target from $210 to $220.
benzinga.com Piper Sandler Maintains Overweight on Neurocrine Biosciences, Raises Price Target to $215 Piper Sandler analyst David Amsellem maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Overweight and raises the price target from $210 to $215.
benzinga.com Neurocrine Biosciences Raises FY 2026 INGREZZA Net Product Sales Guidance from $2.825B-$2.875B to $2.900B-$2.925B Neurocrine Biosciences (NASDAQ:NBIX) Raises FY 2026 INGREZZA Net Product Sales Guidance from $2.825B-$2.875B to $2.900B-$2.925B
benzinga.com Neurocrine Biosciences Q3 Adj. EPS $3.29 Beats $1.91 Estimate, Sales $1.119B Beat $1.043B Estimate Neurocrine Biosciences (NASDAQ:NBIX) reported quarterly earnings of $3.29 per share which beat the analyst consensus estimate of $1.91 by 72.25 percent. This is a 51.61 percent increase over earnings…
benzinga.com Apple, Palantir On Deck Monday As AI Demand, iPhone Growth Face Test Apple headlines Monday’s reports, with investors looking for continued iPhone momentum and evidence that its artificial-intelligence push can support the company’s next leg of growth. Marriott…- benzinga.com Neurocrine Biosciences Identifies Clinically Meaningful Health Improvement Threshold For INGREZZA In Tardive Dyskinesia Patients New analysis establishes a 6-point increase on the EQ Visual Analogue Scale as a threshold for clinically meaningful change in overall health ratings in patients with tardive dyskinesia treated with
- benzinga.com Neurocrine Biosciences Announces Publication Of Expert Perspectives Highlighting Hyperphagia In Prader-Willi Syndrome As Neurobiologically Driven Condition Expert perspectives highlight the interaction of hypothalamic dysfunction, biological, behavioral, and environmental factors in shaping the challenges of hyperphagia in Prader-Willi syndrome for…
benzinga.com Neurocrine Biosciences Starts Phase 2 Clinical Trial Of NBI-1117567 To Treat Adults With Mild To Moderate Alzheimer's Disease Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced the initiation of its Phase 2 clinical study of investigational compound NBI-1117567 (NBI-'567) in adults with mild to moderate Alzheimer's…
benzinga.com Neurocrine Biosciences To Report Impact Of Classical Congenital Adrenal Hyperplasia At Endocrine Nurses Society Annual Symposium 2026 Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced new real-world data demonstrating how the clinical and day-to-day impact of classic congenital adrenal hyperplasia can vary among…- benzinga.com Needham Reiterates Buy on Neurocrine Biosciences, Maintains $204 Price Target Needham analyst Ami Fadia reiterates Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and maintains $204 price target.
benzinga.com 10 Health Care Stocks Whale Activity In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
benzinga.com 10 Health Care Stocks Whale Activity In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
benzinga.com Jim Cramer Says Buy Uber, Calls Rockwell Automation 'One Ugly Chart' but a 'Great Long-Term Situation' Jim Cramer recommended buying Uber, Tanger, Rockwell Automation, Amcor, and Neurocrine Biosciences. Uber and Zipline announced a partnership for autonomous delivery. Tanger and Amcor both reported…
benzinga.com Tom Lee's Small-Cap Granny Shots ETF Reloads: First Solar, Zoom Among 10 New Buys Tom Lee's GRNJ added First Solar, Zoom and eight other stocks in its latest rebalance as assets under management climbed to $476 million.
benzinga.com Earnings Scheduled For May 5, 2026 
benzinga.com Arista Networks To Rally Around 43%? Here Are 10 Top Analyst Forecasts For Tuesday Top Wall Street analysts changed their outlook on top names. See all analyst rating changes, including upgrades and downgrades, on our analyst ratings page.
benzinga.com Neurocrine Buys Soleno To Tap High-Growth Rare Disease Market Neurocrine (NBIX) to acquire Soleno Therapeutics (SLNO) for $2.9B to expand its rare disease portfolio. Get the deal details here.
benzinga.com McDonald's To Rally More Than 14%? Here Are 10 Top Analyst Forecasts For Thursday - benzinga.com Earnings Scheduled For February 11, 2026
benzinga.com Neurocrine's Depression Drug Fails Phase 2 Goal But Shows Encouraging Safety Profile Neurocrine's Phase 2 trial of NBI-1070770 in major depressive disorder missed its main goal but showed good safety and strong Q3 financial results.
benzinga.com S&P 500 Tops 6,900 Ahead Fed Rate Move, Gold Reclaims $4,000: What's Moving Markets Wednesday? A powerful surge in AI-related stocks — led by a 9% advance in NVIDIA Corp. (NASDAQ:NVDA) over the past two sessions — propelled the S&P 500 above the 6,900 mark and lifted the Nasdaq 100 to 26,100…
benzinga.com Earnings Scheduled For October 28, 2025 - benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session Gainers PepGen (NASDAQ: PEPG) shares rose 141.0% to $6.41 during Thursday's pre-market session. The market value of their outstanding shares is at $87.2 million.
- benzinga.com Earnings Scheduled For July 30, 2025
benzinga.com FARO Technologies, Celanese, Avient, Aramark And Other Big Stocks Moving Higher On Tuesday 
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session - benzinga.com Earnings Scheduled For May 5, 2025
- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session
- benzinga.com Earnings Scheduled For February 6, 2025
- benzinga.com Earnings Scheduled For February 7, 2024 Companies Reporting Before The Bell • Madison Square Garden (NYSE:MSGE) is expected to report quarterly loss at $0.80 per share on revenue of $301.83 million.
- benzinga.com Earnings Scheduled For October 31, 2023 Companies Reporting Before The Bell • BBVA (NYSE:BBVA) is likely to report earnings for its third quarter. • BP (NYSE:BP) is expected to report quarterly earnings at $1.37 per share on revenue of…
- benzinga.com Earnings Scheduled For August 1, 2023 Companies Reporting Before The Bell • Toyota Motor (NYSE:TM) is estimated to report earnings for its first quarter. • BP (NYSE:BP) is projected to report quarterly earnings at $1.21 per share on…
- benzinga.com Earnings Scheduled For November 1, 2022 Companies Reporting Before The Bell • BP (NYSE:BP) is estimated to report quarterly earnings at $2.07 per share on revenue of $64.76 billion.
- benzinga.com Earnings Scheduled For August 4, 2022 Companies Reporting Before The Bell • Toyota Motor (NYSE:TM) is projected to report earnings for its first quarter.
- benzinga.com Earnings Scheduled For May 4, 2022 Companies Reporting Before The Bell • Seres Therapeutics (NASDAQ:MCRB) is estimated to report quarterly loss at $0.52 per share on revenue of $8.48 million.
- benzinga.com Stocks That Hit 52-Week Highs On Thursday This morning 168 companies reached new 52-week highs.